Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.31 |
| ▸ | GBA1 | P04062 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18710271 | 1.00 | MAN1B1 (0.36) | MAN1B1TRPA1TRPM8CA2GSR | |
| SCHEMBL9268731 | 1.00 | MAN1B1 (0.36) | MAN1B1TRPA1TRPM8CA2GSR | |
| SCHEMBL21388382 | 1.00 | MAN1B1 (0.36) | MAN1B1TRPA1TRPM8CA2GSR | |
| SCHEMBL12035115 | 0.94 | — | — | |
| SCHEMBL450125 | 0.94 | — | — | |
| SCHEMBL1985004 | 0.94 | — | — | |
| Ammonia Solution, Strong SCHEMBL7958969 | 0.88 | — | — | |
| Bicarbonate SCHEMBL5386575 | 0.82 | CA2 (0.42) | CA2GSRLMNACYP2C9THRB | |
| SCHEMBL25334899 | 0.78 | CA1 (0.47) | TRPA1TRPM8CA2GSRLMNA | |
| SCHEMBL560733 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114058173-A | Process and composition for producing flexible polyurethane foams | 赢创运营有限公司 | 2022-02-18 | — | — | CN | claimed |
| EP-3954722-A1 | PROCESS AND COMPOSITION FOR THE PRODUCTION OF FLEXIBLE POLYURETHANE FOAM | Evonik Operations GmbH (DE) | 2022-02-16 | — | — | EP | claimed |
| US-20220033603-A1 | PROCESS AND COMPOSITION FOR THE PRODUCTION OF FLEXIBLE POLYURETHANE FOAM | EVONIK OPERATIONS GMBH (DE) | 2022-02-03 | — | — | US | claimed |
| US-20070166644-A1 | Photoresist composition and method of forming a photoresist pattern using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2007-07-19 | — | — | US | claimed |
| EP-0957903-A4 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS INC (US) | 2002-10-09 | — | — | EP | claimed |
| US-20020141952-A1 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2002-10-03 | — | — | US | claimed |
| WO-2002051395-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES | CODON PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | claimed |
| EP-0957903-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | Codon Pharmaceuticals, Inc. (US) | 1999-11-24 | — | — | EP | claimed |
| US-5990177-A | CYCLIC AND ACYCLIC MONO-, DI- AND TRIALCOHOLS AS STIMULANTS TO TREAT DISEASES MEDIATED BY DEFICIENCIES IN THE NITRIC OXIDE/CYCLIC GUANOSINE MONOPHOSPHATE/PROTEIN KINASE G SIGNAL TRANSDUCTION PATHWAY; CARDIOVASCULAR; SKIN; NERVOUS SYSTEM | CODON PHARMACEUTICALS, INC. (US) | 1999-11-23 | — | — | US | claimed |
| WO-1998055085-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS, INC. (US) | 1998-12-10 | — | — | WO | claimed |
| WO-1998011882-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS, INC. (US) | 1998-03-26 | — | — | WO | claimed |
| US-3982996-A | CULTURING | STERLING DRUG INC. (US) | 1976-09-28 | — | — | US | claimed |
| US-12594346-B2 | Crosslinked hydrogel for immune checkpoint blockade delivery | GEORGIA TECH RESEARCH CORPORATION (US) | 2026-04-07 | — | — | US | disclosed |
| US-12540224-B2 | Process and composition for the production of flexible polyurethane foam | EVONIK OPERATIONS GMBH (DE) | 2026-02-03 | — | — | US | disclosed |
| US-20250339581-A1 | SYNTHETIC HYDROGEL CARRIERS FOR MUSCLE REPAIR | GEORGIA TECH RES INST (US) | 2025-11-06 | — | — | US | disclosed |
| US-12397084-B2 | Synthetic hydrogel carriers for muscle repair | GEORGIA TECH RESEARCH CORPORATION (US) | 2025-08-26 | — | — | US | disclosed |
| EP-0583605-A1 | Defined oligomeric liquid crystalline compounds with smectic liquid crystalline phases | BASF Aktiengesellschaft (DE) | 1994-02-23 | — | — | EP | disclosed |
| EP-0528268-A2 | Optically active esters of phenoxypropionic acid | BASF Aktiengesellschaft (DE) | 1993-02-24 | — | — | EP | disclosed |
| EP-0504660-A2 | Liquid crystal compounds | BASF Aktiengesellschaft (DE) | 1992-09-23 | — | — | EP | disclosed |
| US-3982996-A | CULTURING | STERLING DRUG INC. (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540224-B2 | Process and composition for the production of flexible polyurethane foam | INTS9, PUF60, INTS6 | MAN1B1 3943/4885TRPA1 687/4885TRPM8 2657/4885 |
| US-20220033603-A1 | PROCESS AND COMPOSITION FOR THE PRODUCTION OF FLEXIBLE POLYURETHANE FOAM | PUF60, FUS, PCBP1 | MAN1B1 1886/4885TRPA1 1044/4885TRPM8 3695/4885 |
| US-20020141952-A1 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | TYR, MITF, MC1R | MAN1B1 3320/4885TRPA1 2949/4885TRPM8 2669/4885 |
| US-12594346-B2 | Crosslinked hydrogel for immune checkpoint blockade delivery | CD274, PDCD1, IL2 | MAN1B1 3757/4885TRPA1 4771/4885TRPM8 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.